

April 6, 2026

The Honorable Jim Jordan
Chairman
House Committee on the Judiciary
2056 Rayburn House Office Building
Washington, DC 20515

The Honorable Jamie Raskin
Ranking Member
House Committee on the Judiciary
2242 Rayburn House Office Building
Washington, DC 20515

The Honorable Darrell Issa
Chairman
Subcommittee on Courts, IP,
AI, and the Internet
2108 Rayburn House Office Building
Washington, DC 20515

The Honorable Henry C. Johnson
Ranking Member
Subcommittee on Courts, IP,
AI, and the Internet
2240 Rayburn House Office Building
Washington, DC 20515

RE: Skinny Labels, Big Savings Act (H.R. 6485), Eliminating Thickets to Increase Competition (ETHIC) Act (H.R. 3269)

Dear Chairman Jordan, Chairman Issa, Ranking Member Raskin, and Ranking Member Johnson:

We, the undersigned list of 20 organizations, urge you to hold a hearing and advance crucial legislation to help reduce costs for America's patients. Specifically, we urge you to take action on two bills which have bipartisan support – (1) the *Skinny Labels, Big Savings Act (H.R. 6485)*, introduced by Representatives Ben Cline (R-VA) and Zoe Lofgren (D-CA), as well as (2) the *Eliminating Thickets to Increase Competition (ETHIC) Act (H.R. 3269)*, introduced by Representatives Jodey Arrington (R-TX), Lloyd Doggett (D-TX), Darrell Issa (R-CA), and Pramila Jayapal (D-WA).

The *Skinny Labels Big Savings Act (H.R. 6485)* will ensure that the Hatch-Waxman Act's longstanding provisions regarding skinny labels are not undermined and that patients can continue to access lower-cost medicines as quickly as possible. Skinny labels allow the generic manufacturer to "carve-out" a brand drug sponsor's patented methods of use from the generic's FDA-approved labeling. That carve-out process has served the public interest for over 40 years by increasing access to generic medicines, saving the healthcare system billions of dollars.

According to The American Journal of Managed Care (AJMC), from 2015 to 2020, [15 skinny labels alone generated \\$14.6 Billion in Medicare savings](#). Without explicit protection for carve-outs, the existence of a single, indication-specific patent could block generic and biosimilar versions from entering the market, the *Skinny Labels, Big Savings Act*—would reverse a mistaken decision by the U.S. Court of Appeals for the Federal Circuit which, according to the federal government, "threatens significant harm to competition and to consumers."

The *ETHIC Act (H.R. 3269)* will enhance patient access by preventing brand-name pharmaceutical companies from asserting multiple duplicative patents in patent litigation. These duplicative patents create a numbers game for generic and biosimilar companies that ultimately harms patients. Indeed, challenging a large patent estate requires generic and biosimilar manufacturers to engage in years

of slow-moving and costly patent litigation to bring their lower-cost medicines to market. The net result is delayed patient access to lower-cost generics and biosimilar medicines. This legislation helps address this patent litigation bottleneck—while also respecting innovation—by requiring brand-name pharmaceuticals to assert only non-duplicative patents in patent litigation.

We look forward to continuing to work with you, as leaders of the committees of jurisdiction, to achieve the enactment of these crucial bills as soon as possible.

Sincerely,

Academy of Managed Care Pharmacy
AHIP
Alliance of Community Health Plans
American Consumer Institute
American Society of Health-System Pharmacists
ASCP (American Society of Consultant Pharmacists)
Association for Accessible Medicines
Blue Cross Blue Shield Association
Campaign for Sustainable Rx Pricing
Consumer Action
Generation Patient
National Alliance of Healthcare Purchaser Coalitions
National Consumers League
PCMA
Public Citizen
R Street Institute
The ERISA Industry Committee
Transparency-Rx
US*MADE
U.S. PIRG